StockNews.com Issues Positive Rating for MEI Pharma StockNews.com has initiated coverage on MEI Pharma with a "buy" rating. The stock, which recently opened at $2.43, is trading near its 52-week low of $2.30. Despite challenges, analysts remain optimistic about the company’s potential in cancer treatment development, including its key therapies, Zandelisib and Voruciclib.2